RecruitingNCT05007990
Caregiving Networks Across Disease Context and the Life Course
Studying GM2 gangliosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Human Genome Research Institute (NHGRI)
- Principal Investigator
- Laura M Koehly, Ph.D.National Human Genome Research Institute (NHGRI)
- Enrollment
- 2800 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2030
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05007990 on ClinicalTrials.govOther trials for GM2 gangliosidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07399704A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseAzafaros A.G.
- ACTIVE NOT RECRUITINGNCT06614569Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff DiseaseTerence Flotte
- ACTIVE NOT RECRUITINGPHASE2NCT05758922Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C DiseaseAzafaros A.G.